Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

M. Morfouace; S. Novello; A. Stevovic; C. Dooms; U. Janžič; T. Berghmans; R. Dziadziuszko; T. Gorlia; E. Felip; L. Paz-Ares; J. Mazieres; M. O’Brien; P. Bironzo; J. Vansteenkiste; L. Lacroix; A. C. Dingemans; V. Golfinopoulos; B. Besse

doi:10.1038/s41598-022-12056-0

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

M. Morfouace^*, S. Novello, A. Stevovic, C. Dooms, U. Janžič, T. Berghmans, R. Dziadziuszko, T. Gorlia, E. Felip, L. Paz-Ares, J. Mazieres, M. O’Brien, P. Bironzo, J. Vansteenkiste, L. Lacroix, A. C. Dingemans, V. Golfinopoulos, B. Besse

^*Corresponding author for this work

Pulmonary Medicine

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

17 Downloads (Pure)

Abstract

Access to a comprehensive molecular alteration screening is patchy in Europe and quality of the molecular analysis varies. SPECTAlung was created in 2015 as a pan-European screening platform for patients with thoracic malignancies. Here we report the results of almost 4 years of prospective molecular screening of patients with thoracic malignancies, in terms of quality of the program and molecular alterations identified. Patients with thoracic malignancies at any stage of disease were recruited in SPECTAlung, from June 2015 to May 2019, in 7 different countries. Molecular tumour boards were organised monthly to discuss patients’ molecular and clinical profile and possible biomarker-driven treatments, including clinical trial options. FFPE material was collected and analysed for 576 patients with diagnosis of pleural, lung, or thymic malignancies. Ultimately, 539 patients were eligible (93.6%) and 528 patients were assessable (91.7%). The turn-around time for report generation and molecular tumour board was 214 days (median). Targetable molecular alterations were observed in almost 20% of cases, but treatment adaptation was low (3% of patients). SPECTAlung showed the feasibility of a pan-European screening platform. One fifth of the patients had a targetable molecular alteration. Some operational issues were discovered and adapted to improve efficiency.

Original language	English
Article number	8342
Journal	Scientific Reports
Volume	12
Issue number	1
DOIs	https://doi.org/10.1038/s41598-022-12056-0
Publication status	Published - 18 May 2022

Bibliographical note

Funding Information:
This publication was supported by Fonds Baillet Latour from Belgium and Walgreens Boots Alliance. We would like to thank the patients, physicians, nurses, and trial coordinators who participated in the SPECTAlung project. From the EORTC headquarters, we would like to acknowledge Maarten Spruyt (DM), Alexandra Jouret (COM), and Maira Seini (RA).

Funding Information:
This publication was supported by Fonds Baillet Latour from Belgium and Walgreens Boots Alliance.

Publisher Copyright:
© 2022, The Author(s).

Access to Document

10.1038/s41598-022-12056-0Licence: CC BY

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platformFinal published version, 4.21 MBLicence: CC BY

Cite this

Morfouace, M., Novello, S., Stevovic, A., Dooms, C., Janžič, U., Berghmans, T., Dziadziuszko, R., Gorlia, T., Felip, E., Paz-Ares, L., Mazieres, J., O’Brien, M., Bironzo, P., Vansteenkiste, J., Lacroix, L., Dingemans, A. C., Golfinopoulos, V., & Besse, B. (2022). Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform. Scientific Reports, 12(1), Article 8342. https://doi.org/10.1038/s41598-022-12056-0

@article{7d6e1c39cf3f46f281536add05e4f5e4,

title = "Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform",

abstract = "Access to a comprehensive molecular alteration screening is patchy in Europe and quality of the molecular analysis varies. SPECTAlung was created in 2015 as a pan-European screening platform for patients with thoracic malignancies. Here we report the results of almost 4 years of prospective molecular screening of patients with thoracic malignancies, in terms of quality of the program and molecular alterations identified. Patients with thoracic malignancies at any stage of disease were recruited in SPECTAlung, from June 2015 to May 2019, in 7 different countries. Molecular tumour boards were organised monthly to discuss patients{\textquoteright} molecular and clinical profile and possible biomarker-driven treatments, including clinical trial options. FFPE material was collected and analysed for 576 patients with diagnosis of pleural, lung, or thymic malignancies. Ultimately, 539 patients were eligible (93.6%) and 528 patients were assessable (91.7%). The turn-around time for report generation and molecular tumour board was 214 days (median). Targetable molecular alterations were observed in almost 20% of cases, but treatment adaptation was low (3% of patients). SPECTAlung showed the feasibility of a pan-European screening platform. One fifth of the patients had a targetable molecular alteration. Some operational issues were discovered and adapted to improve efficiency.",

author = "M. Morfouace and S. Novello and A. Stevovic and C. Dooms and U. Jan{\v z}i{\v c} and T. Berghmans and R. Dziadziuszko and T. Gorlia and E. Felip and L. Paz-Ares and J. Mazieres and M. O{\textquoteright}Brien and P. Bironzo and J. Vansteenkiste and L. Lacroix and Dingemans, {A. C.} and V. Golfinopoulos and B. Besse",

note = "Funding Information: This publication was supported by Fonds Baillet Latour from Belgium and Walgreens Boots Alliance. We would like to thank the patients, physicians, nurses, and trial coordinators who participated in the SPECTAlung project. From the EORTC headquarters, we would like to acknowledge Maarten Spruyt (DM), Alexandra Jouret (COM), and Maira Seini (RA). Funding Information: This publication was supported by Fonds Baillet Latour from Belgium and Walgreens Boots Alliance. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = may,

day = "18",

doi = "10.1038/s41598-022-12056-0",

language = "English",

volume = "12",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

Morfouace, M, Novello, S, Stevovic, A, Dooms, C, Janžič, U, Berghmans, T, Dziadziuszko, R, Gorlia, T, Felip, E, Paz-Ares, L, Mazieres, J, O’Brien, M, Bironzo, P, Vansteenkiste, J, Lacroix, L, Dingemans, AC, Golfinopoulos, V & Besse, B 2022, 'Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform', Scientific Reports, vol. 12, no. 1, 8342. https://doi.org/10.1038/s41598-022-12056-0

TY - JOUR

T1 - Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

AU - Morfouace, M.

AU - Novello, S.

AU - Stevovic, A.

AU - Dooms, C.

AU - Janžič, U.

AU - Berghmans, T.

AU - Dziadziuszko, R.

AU - Gorlia, T.

AU - Felip, E.

AU - Paz-Ares, L.

AU - Mazieres, J.

AU - O’Brien, M.

AU - Bironzo, P.

AU - Vansteenkiste, J.

AU - Lacroix, L.

AU - Dingemans, A. C.

AU - Golfinopoulos, V.

AU - Besse, B.

N1 - Funding Information: This publication was supported by Fonds Baillet Latour from Belgium and Walgreens Boots Alliance. We would like to thank the patients, physicians, nurses, and trial coordinators who participated in the SPECTAlung project. From the EORTC headquarters, we would like to acknowledge Maarten Spruyt (DM), Alexandra Jouret (COM), and Maira Seini (RA). Funding Information: This publication was supported by Fonds Baillet Latour from Belgium and Walgreens Boots Alliance. Publisher Copyright: © 2022, The Author(s).

PY - 2022/5/18

Y1 - 2022/5/18

N2 - Access to a comprehensive molecular alteration screening is patchy in Europe and quality of the molecular analysis varies. SPECTAlung was created in 2015 as a pan-European screening platform for patients with thoracic malignancies. Here we report the results of almost 4 years of prospective molecular screening of patients with thoracic malignancies, in terms of quality of the program and molecular alterations identified. Patients with thoracic malignancies at any stage of disease were recruited in SPECTAlung, from June 2015 to May 2019, in 7 different countries. Molecular tumour boards were organised monthly to discuss patients’ molecular and clinical profile and possible biomarker-driven treatments, including clinical trial options. FFPE material was collected and analysed for 576 patients with diagnosis of pleural, lung, or thymic malignancies. Ultimately, 539 patients were eligible (93.6%) and 528 patients were assessable (91.7%). The turn-around time for report generation and molecular tumour board was 214 days (median). Targetable molecular alterations were observed in almost 20% of cases, but treatment adaptation was low (3% of patients). SPECTAlung showed the feasibility of a pan-European screening platform. One fifth of the patients had a targetable molecular alteration. Some operational issues were discovered and adapted to improve efficiency.

AB - Access to a comprehensive molecular alteration screening is patchy in Europe and quality of the molecular analysis varies. SPECTAlung was created in 2015 as a pan-European screening platform for patients with thoracic malignancies. Here we report the results of almost 4 years of prospective molecular screening of patients with thoracic malignancies, in terms of quality of the program and molecular alterations identified. Patients with thoracic malignancies at any stage of disease were recruited in SPECTAlung, from June 2015 to May 2019, in 7 different countries. Molecular tumour boards were organised monthly to discuss patients’ molecular and clinical profile and possible biomarker-driven treatments, including clinical trial options. FFPE material was collected and analysed for 576 patients with diagnosis of pleural, lung, or thymic malignancies. Ultimately, 539 patients were eligible (93.6%) and 528 patients were assessable (91.7%). The turn-around time for report generation and molecular tumour board was 214 days (median). Targetable molecular alterations were observed in almost 20% of cases, but treatment adaptation was low (3% of patients). SPECTAlung showed the feasibility of a pan-European screening platform. One fifth of the patients had a targetable molecular alteration. Some operational issues were discovered and adapted to improve efficiency.

UR - http://www.scopus.com/inward/record.url?scp=85130279716&partnerID=8YFLogxK

U2 - 10.1038/s41598-022-12056-0

DO - 10.1038/s41598-022-12056-0

M3 - Article

C2 - 35585228

AN - SCOPUS:85130279716

SN - 2045-2322

VL - 12

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 8342

ER -

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this